|
Toggle Summary
February 22, 2016
|
Minerva Neurosciences Announces Completion of Patient Enrollment in Phase IIa Trial of MIN-117 in Major Depressive Disorder
|
Minerva Neurosciences Announces Completion of Patient Enrollment in Phase IIa Trial of MIN-117 in Major Depressive Disorder
|
|
Toggle Summary
February 1, 2016
|
Minerva Neurosciences Announces Top Line Data From MIN-202 Phase I Clinical Study in Japanese Patients
|
Minerva Neurosciences Announces Top Line Data From MIN-202 Phase I Clinical Study in Japanese Patients
|
|
Toggle Summary
January 11, 2016
|
Minerva Neurosciences Announces Favorable Top Line Results From MIN-202 Phase 2A Clinical Trial in Insomnia Disorder
Consistent Improvements Observed With Selective Orexin-2 Receptor Antagonist in Multiple Parameters of Sleep Induction and Maintenance
|
Minerva Neurosciences Announces Favorable Top Line Results From MIN-202 Phase 2A Clinical Trial in Insomnia Disorder
|
|
Toggle Summary
December 29, 2015
|
Minerva Neurosciences Announces Update on MIN-101 Clinical Development Program
Enrollment Completed in European Phase IIb Trial and Investigational New Drug (IND) Application Accepted by U.S. FDA
|
Minerva Neurosciences Announces Update on MIN-101 Clinical Development Program
|
|
Toggle Summary
December 18, 2015
|
Minerva Achieves Enrollment Target in Phase IIb Trial With MIN-101
WALTHAM, Mass., Dec. 18, 2015 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it has met its enrollment target of 234 patients in
|
Minerva Achieves Enrollment Target in Phase IIb Trial With MIN-101
|
|
Toggle Summary
December 9, 2015
|
Minerva Provides Year-End Update on Clinical Trials With Three Central Nervous System Product Candidates
Patient Enrollment Progress During 2015 Confirms Timeline Expectations for Topline Data Availability From Four Trials in First Half of 2016
|
Minerva Provides Year-End Update on Clinical Trials With Three Central Nervous System Product Candidates
|
|
Toggle Summary
November 13, 2015
|
Minerva Neurosciences to Present at Jefferies 2015 London Healthcare Conference on November 18, 2015
|
Minerva Neurosciences to Present at Jefferies 2015 London Healthcare Conference on November 18, 2015
|
|
Toggle Summary
November 5, 2015
|
Minerva Neurosciences Reports Third Quarter 2015 Financial Results and Business Updates
|
Minerva Neurosciences Reports Third Quarter 2015 Financial Results and Business Updates
|
|
Toggle Summary
November 2, 2015
|
Minerva Neurosciences Announces Appointment of Dr. David Kupfer to Its Board of Directors
|
Minerva Neurosciences Announces Appointment of Dr. David Kupfer to Its Board of Directors
|
|
Toggle Summary
October 29, 2015
|
Minerva Neurosciences to Report Third Quarter 2015 Financial Results and Host Conference Call on November 5, 2015
|
Minerva Neurosciences to Report Third Quarter 2015 Financial Results and Host Conference Call on November 5, 2015
|
